Applied Therapeutics (APLT) Projected to Post Earnings on Wednesday

Applied Therapeutics (NASDAQ:APLT - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Wednesday, March 5th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $0.10 million for the quarter.

Applied Therapeutics Price Performance

Shares of Applied Therapeutics stock traded down $0.00 during trading on Friday, hitting $0.51. The stock had a trading volume of 3,075,258 shares, compared to its average volume of 4,564,848. The firm has a market cap of $59.16 million, a P/E ratio of -0.32 and a beta of 1.88. The business has a fifty day moving average of $0.66 and a two-hundred day moving average of $4.58. Applied Therapeutics has a fifty-two week low of $0.49 and a fifty-two week high of $10.62.

Wall Street Analyst Weigh In

APLT has been the subject of several research analyst reports. Citigroup cut their price objective on Applied Therapeutics from $13.00 to $8.00 and set a "buy" rating for the company in a report on Friday, November 29th. UBS Group restated a "neutral" rating and issued a $2.00 price objective (down previously from $13.00) on shares of Applied Therapeutics in a report on Monday, December 2nd. Robert W. Baird reduced their target price on Applied Therapeutics from $14.00 to $5.00 and set an "outperform" rating for the company in a report on Friday, November 29th. Royal Bank of Canada reduced their target price on Applied Therapeutics from $4.00 to $1.50 and set a "sector perform" rating for the company in a report on Friday, December 20th. Finally, William Blair downgraded Applied Therapeutics from an "outperform" rating to a "market perform" rating in a report on Monday, December 23rd. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $6.10.

Remove Ads

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.